Financial Times, Jan. 31, 2008 Vertex's lead drug telaprevir, for the treatment of hepatitis C, will have to be monitored for the emergence of drug resistance, physicians say. The article quotes Dr. Ned Snyder, professor of internal medicine in the Division of Gastroenterology at UTMB.